The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)
Launched by INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT · Jul 10, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The TRIple Elimination Model Of Mother-to-child Transmission Program, or TRI-MOM, is a clinical trial focused on preventing the transmission of HIV, syphilis, and hepatitis B (HBV) from mothers to their babies. This program is being tested in five health facilities in Burkina Faso and five in The Gambia. It uses simple and affordable tests to help healthcare workers better screen and treat pregnant women for these infections, aiming to strengthen the care they receive during and after pregnancy.
If you are a woman attending a postnatal visit at one of the participating health centers, you may be eligible to join this study. There are no age limits for participation, but you would need to agree to take part and be able to provide your consent. As a participant, you can expect to help improve health services for mothers and their babies while also receiving support in managing any health risks associated with these infections. Your involvement could contribute to important changes in how healthcare is delivered in your community.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women attending a postnatal visit in one of the selected maternities (no maternal age limit)
- Exclusion Criteria:
- • Refusal to participate in the study
- • Unable to provide consent
About Institut De Recherche Pour Le Developpement
The Institut de Recherche pour le Développement (IRD) is a prominent French research organization dedicated to advancing knowledge and innovation in the fields of sustainable development, health, and environmental sciences. With a multidisciplinary approach, the IRD collaborates with international partners to conduct high-impact clinical trials and research initiatives that address pressing global health challenges. By integrating scientific research with practical applications, the institute aims to enhance public health outcomes and contribute to the development of effective health policies and interventions in diverse contexts.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bobo Dioulasso, , Burkina Faso
Fajara, , Gambia
Patients applied
Trial Officials
Sylvie Boyer, PhD
Principal Investigator
UMR 1252 SESSTIM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported